PSCA CAR-T (Zhaotai Cell)

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NamePSCA CAR-T (Zhaotai Cell)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Source of cells > PMBC-derived
Mechanisms of ActionAnti-PSCA
TargetsProstate stem cell antigen
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGuangdong Zhaotai Cell Bio-tech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGuangdong Zhaotai Invivo Biomedicine Co LtdFirst People'S Hoapital Of FoshanHunan Zhaotai Yongren Medical Innovation Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungLung Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A